MedTrace Logo

Safety and Tolerability Study of GSK1120212, a MEK Inhibitor, in Combination With Docetaxel, Erlotinib, Pemetrexed, Pemetrexed + Carboplatin, Pemetrexed + Cisplatin, or Nab-Paclitaxel

NCT01192165 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 169

Last updated 2017-11-13

No results posted yet for this study

Summary

The purpose of this study is to determine what dose of GSK1120212 can be given safely in combination with at least one other drug that is already approved to treat cancer. This study will test the safety of up to 6 different GSK1120212 study treatment combinations (GSK1120212 plus either docetaxel, erlotinib, pemetrexed, pemetrexed + carboplatin, pemetrexed + cisplatin, or nab-paclitaxel). The doses identified in this study may be used in future trials to test whether the combination treatment is a safe and effective therapy for subjects with metastatic lung and/or pancreatic cancers.

Conditions

Interventions

DRUG

Trametinib (GSK1120212)

Investigational small molecule targeted therapy (MEK1/2 inhibitor)

DRUG

Docetaxel

Chemotherapy

DRUG

Erlotinib

Small molecule targeted therapy (EGFR inhibitor)

DRUG

Pemetrexed

Chemotherapy

DRUG

Carboplatin

Chemotherapy

DRUG

nab-Paclitaxel

Chemotherapy

DRUG

Cisplatin

Chemotherapy

Sponsors & Collaborators

Principal Investigators

  • GSK Clinical Trials · GlaxoSmithKline

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-09-14
Primary Completion
2013-10-07
Completion
2013-10-07

Countries

  • United States
  • Canada
  • France
  • South Korea

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01192165 on ClinicalTrials.gov